T-cell lymphomaLYMPHOMASLACTATE dehydrogenaseOVERALL survivalBackground: Extranodal natural killer/ T‐cell lymphoma (ENKTL) is a rare malignant tumor. This study aimed to develop a predictive nomogram and a web‐based survival rate calculator for dynamically predicting the survival of patients ...
and the median progression-free survival for treated patients with Hodgkin lymphoma (n=11) has not been reached. The median overall survival for all treated patients has not been reached. Interpretation: Anti-CD30 CAR T-cell infusio...
淋巴结活检发现不典型淋巴样细胞浸润,其免疫组化显示CD2、CD3、CD4、CD5、B细胞淋巴瘤2(B-celllymphoma 2, BCL2)、MUM1、T细胞受体β(T-cell receptor β, TCR β)、程序性死亡受体1(programmed cell death 1, PD1)和CD25(片状)阳性,CD20、BCL5、CD10、...
6g). Intriguingly, treatment of mice with CD1a-CAR T cells, which target T-leukemic cells, markedly suppressed FLNA-overexpressing Molt4-luc cell growth and prolonged the survival of NSG mice (Fig. 7d–f). Together, these data suggest that T-leukemic cells use mechanical softness to impede ...
Survival outcomes for extranodal natural-killer T-cell lymphomadoi:10.1016/S2352-3026(20)30112-5Motoharu ShibusawaTetsuya TanimotoThe Lancet Haematology
T-cell lymphomaT cell non-Hodgkin lymphoma (T-NHL) is highly invasive and heterogeneous without accurate prognosis prediction. We proposed peripheral CD16/CD16 + monocytes the additional indicators for T-NHL prognosis. We prospectively recruited 31 T-NHL patients without previous treatment. The CD...
The PNI is a powerful predictor of survival in ENKTL. Nutritional status and inflammatory responses at diagnosis might play an important role in survival in patients with ENKTL. 展开 关键词: Extranodal NK/T cell lymphoma Nasal type Prognostic nutritional index Prognostic factors ...
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
3、Bastos‐Oreiro M, Abrisqueta P, Gutierrez A, et al. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group[J]. HemaSphere, 2024, 8(4). 4、Choquet S, Soussain C,...
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy arising from aberrant proliferation of immature T cell progenitors and accounts for about 15% of pediatric ALL cases1. The current risk-adapted, multiagent chemotherapeutic regimen has led to an overall survival rate exceeding ...